Tempus AI shares rise 5% pre-market on continued momentum, Ambry Genetics acquisition
Shares of Tempus AI , Inc. (NASDAQ:TEM) climbed 5% in pre-open trading Tuesday following the completion of its acquisition of ...
Nature6y
Breaking new ground through high-quality genetic testing
Ambry Genetics drives innovation in diagnostics by launching cutting-edge genetic tests and technologies. Its broad collaborations, novel research projects, and networks for data sharing ...
TMCnet7d
Tempus Completes Acquisition of Ambry Genetics
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its acquisition of Ambry Genetics, a ...
Tempus AI (TEM) Acquires Ambry Genetics in $600M Precision Medicine Push
We recently published a list of Top 10 AI Stocks Trending On Wall Street. In this article, we are going to take a look at ...
Morningstar1mon
Ambry Genetics Data Supports Functional Study of BRCA2, Helping Improve Variant Classification for Hereditary BRCA2-Linked Cancers
Together, these studies represent a major step forward in variant classification, providing essential data that helps clinicians better assess cancer risks tied to genetic mutations. Ambry ...
The Scientist6y
Study Finds Inaccuracies in 40 Percent of DTC Genetic Testing Results
“Such a high rate of a false positives in this particular study was unexpected,” says study coauthor Stephany Tandy-Connor of Ambry Genetics, in a statement. She notes that differences in testing ...
Yahoo Finance5d
TD Cowen reinstates coverage on Tempus AI with 'buy' after Ambry deal
Ambry, a 25-year-old genetics testing firm, is expected to generate over $300 million in revenue this year, with growth boosted by market share gains following Invitae’s bankruptcy.